GSK plc (LON:GSK) Given Consensus Recommendation of “Hold” by Brokerages

Shares of GSK plc (LON:GSK) have received a consensus rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is GBX 1,917.86.

GSK has been the subject of several research analyst reports. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. UBS Group reissued a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 2,300 target price on shares of GSK in a report on Wednesday, February 4th. Berenberg Bank increased their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 2,100 price target on shares of GSK in a report on Wednesday, January 7th.

Insider Buying and Selling at GSK

In related news, insider Wendy Becker bought 441 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were acquired at an average price of GBX 1,809 per share, with a total value of £7,977.69. Also, insider Luke Miels sold 4,549 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of GBX 2,211, for a total value of £100,578.39. In the last ninety days, insiders have purchased 4,597 shares of company stock worth $9,082,343. 0.20% of the stock is currently owned by insiders.

GSK Stock Performance

Shares of GSK stock opened at GBX 2,227.40 on Tuesday. The stock’s 50-day moving average is GBX 1,888.13 and its two-hundred day moving average is GBX 1,702.91. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 2,230. The firm has a market cap of £89.87 billion, a price-to-earnings ratio of 16.75, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts predict that GSK will post 175.980975 earnings per share for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.